| Miss Casey Jo Bube, APNP | |
|
2400 Pine Ridge Blvd, Wausau, WI 54401-7803 | |
| (715) 847-2022 | |
| Not Available |
| Full Name | Miss Casey Jo Bube |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Location | 2400 Pine Ridge Blvd, Wausau, Wisconsin |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679059091 | NPI | - | NPPES |
| Entity Name | Aspirus Rhinelander & Tomahawk Hospitals & Clinics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144991340 PECOS PAC ID: 9335059856 Enrollment ID: O20031126000706 |
News Archive
Amgen today announced detailed results from a new biomarker analysis of the pivotal Phase 3 "408" trial of Vectibix® (panitumumab) plus best supportive care compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigate whether mutations in nine genes known to be mutated in colorectal cancer, including the previously unanalyzed exon 3 mutation of the KRAS gene, are predictive of response to Vectibix in metastatic colorectal cancer.
A surgical treatment that stimulates distressed neural networks through electrodes threaded directly into a person's brain has quietly made a difference in the lives of tens of thousands of people with Parkinson disease, essential tremor, and dystonia over the course of the past decade. But while it steadies patients' shaking limbs with surprising effect, its benefits on some patients' minds and personal lives have been more mixed.
The Department of Veterans Affairs will increase its corps of mental health professionals to try to cope with the increased demand from vets of the Iraq and Afghanistan wars.
Abbott today announced positive six-month results from the first 45 patients enrolled in the second stage of the ABSORB trial, which was presented during the Late-Breaking Clinical Trials session at the EuroPCR 2010 conference. At six months, Abbott's bioresorbable vascular scaffold (BVS) demonstrated strong results, with a low (4.4 percent) rate of major adverse cardiac events (MACE) and no blood clots (thromboses).
South African AIDS activist Thembi Ngubane recently died of drug-resistant tuberculosis at the age of 24, the AP/Washington Post reports (Nullis, AP/Washington Post, 6/14).
› Verified 8 days ago
| Entity Name | Aspirus Merrill Hospital & Clinics Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1124084678 PECOS PAC ID: 0143117556 Enrollment ID: O20040301001179 |
News Archive
Amgen today announced detailed results from a new biomarker analysis of the pivotal Phase 3 "408" trial of Vectibix® (panitumumab) plus best supportive care compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigate whether mutations in nine genes known to be mutated in colorectal cancer, including the previously unanalyzed exon 3 mutation of the KRAS gene, are predictive of response to Vectibix in metastatic colorectal cancer.
A surgical treatment that stimulates distressed neural networks through electrodes threaded directly into a person's brain has quietly made a difference in the lives of tens of thousands of people with Parkinson disease, essential tremor, and dystonia over the course of the past decade. But while it steadies patients' shaking limbs with surprising effect, its benefits on some patients' minds and personal lives have been more mixed.
The Department of Veterans Affairs will increase its corps of mental health professionals to try to cope with the increased demand from vets of the Iraq and Afghanistan wars.
Abbott today announced positive six-month results from the first 45 patients enrolled in the second stage of the ABSORB trial, which was presented during the Late-Breaking Clinical Trials session at the EuroPCR 2010 conference. At six months, Abbott's bioresorbable vascular scaffold (BVS) demonstrated strong results, with a low (4.4 percent) rate of major adverse cardiac events (MACE) and no blood clots (thromboses).
South African AIDS activist Thembi Ngubane recently died of drug-resistant tuberculosis at the age of 24, the AP/Washington Post reports (Nullis, AP/Washington Post, 6/14).
› Verified 8 days ago
| Entity Name | Surgical Associates Sc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710910476 PECOS PAC ID: 3072400019 Enrollment ID: O20040303000627 |
News Archive
Amgen today announced detailed results from a new biomarker analysis of the pivotal Phase 3 "408" trial of Vectibix® (panitumumab) plus best supportive care compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigate whether mutations in nine genes known to be mutated in colorectal cancer, including the previously unanalyzed exon 3 mutation of the KRAS gene, are predictive of response to Vectibix in metastatic colorectal cancer.
A surgical treatment that stimulates distressed neural networks through electrodes threaded directly into a person's brain has quietly made a difference in the lives of tens of thousands of people with Parkinson disease, essential tremor, and dystonia over the course of the past decade. But while it steadies patients' shaking limbs with surprising effect, its benefits on some patients' minds and personal lives have been more mixed.
The Department of Veterans Affairs will increase its corps of mental health professionals to try to cope with the increased demand from vets of the Iraq and Afghanistan wars.
Abbott today announced positive six-month results from the first 45 patients enrolled in the second stage of the ABSORB trial, which was presented during the Late-Breaking Clinical Trials session at the EuroPCR 2010 conference. At six months, Abbott's bioresorbable vascular scaffold (BVS) demonstrated strong results, with a low (4.4 percent) rate of major adverse cardiac events (MACE) and no blood clots (thromboses).
South African AIDS activist Thembi Ngubane recently died of drug-resistant tuberculosis at the age of 24, the AP/Washington Post reports (Nullis, AP/Washington Post, 6/14).
› Verified 8 days ago
| Entity Name | Aspirus Eagle River Hospital & Clinics, Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346204385 PECOS PAC ID: 1658361951 Enrollment ID: O20040518000233 |
News Archive
Amgen today announced detailed results from a new biomarker analysis of the pivotal Phase 3 "408" trial of Vectibix® (panitumumab) plus best supportive care compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigate whether mutations in nine genes known to be mutated in colorectal cancer, including the previously unanalyzed exon 3 mutation of the KRAS gene, are predictive of response to Vectibix in metastatic colorectal cancer.
A surgical treatment that stimulates distressed neural networks through electrodes threaded directly into a person's brain has quietly made a difference in the lives of tens of thousands of people with Parkinson disease, essential tremor, and dystonia over the course of the past decade. But while it steadies patients' shaking limbs with surprising effect, its benefits on some patients' minds and personal lives have been more mixed.
The Department of Veterans Affairs will increase its corps of mental health professionals to try to cope with the increased demand from vets of the Iraq and Afghanistan wars.
Abbott today announced positive six-month results from the first 45 patients enrolled in the second stage of the ABSORB trial, which was presented during the Late-Breaking Clinical Trials session at the EuroPCR 2010 conference. At six months, Abbott's bioresorbable vascular scaffold (BVS) demonstrated strong results, with a low (4.4 percent) rate of major adverse cardiac events (MACE) and no blood clots (thromboses).
South African AIDS activist Thembi Ngubane recently died of drug-resistant tuberculosis at the age of 24, the AP/Washington Post reports (Nullis, AP/Washington Post, 6/14).
› Verified 8 days ago
| Entity Name | Aspirus Stevens Point Hospital & Clinics, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1538112230 PECOS PAC ID: 1850358938 Enrollment ID: O20041210000558 |
News Archive
Amgen today announced detailed results from a new biomarker analysis of the pivotal Phase 3 "408" trial of Vectibix® (panitumumab) plus best supportive care compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigate whether mutations in nine genes known to be mutated in colorectal cancer, including the previously unanalyzed exon 3 mutation of the KRAS gene, are predictive of response to Vectibix in metastatic colorectal cancer.
A surgical treatment that stimulates distressed neural networks through electrodes threaded directly into a person's brain has quietly made a difference in the lives of tens of thousands of people with Parkinson disease, essential tremor, and dystonia over the course of the past decade. But while it steadies patients' shaking limbs with surprising effect, its benefits on some patients' minds and personal lives have been more mixed.
The Department of Veterans Affairs will increase its corps of mental health professionals to try to cope with the increased demand from vets of the Iraq and Afghanistan wars.
Abbott today announced positive six-month results from the first 45 patients enrolled in the second stage of the ABSORB trial, which was presented during the Late-Breaking Clinical Trials session at the EuroPCR 2010 conference. At six months, Abbott's bioresorbable vascular scaffold (BVS) demonstrated strong results, with a low (4.4 percent) rate of major adverse cardiac events (MACE) and no blood clots (thromboses).
South African AIDS activist Thembi Ngubane recently died of drug-resistant tuberculosis at the age of 24, the AP/Washington Post reports (Nullis, AP/Washington Post, 6/14).
› Verified 8 days ago
| Entity Name | Dispatchhealth - Arizona |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1194398511 PECOS PAC ID: 7810268422 Enrollment ID: O20210827001139 |
News Archive
Amgen today announced detailed results from a new biomarker analysis of the pivotal Phase 3 "408" trial of Vectibix® (panitumumab) plus best supportive care compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigate whether mutations in nine genes known to be mutated in colorectal cancer, including the previously unanalyzed exon 3 mutation of the KRAS gene, are predictive of response to Vectibix in metastatic colorectal cancer.
A surgical treatment that stimulates distressed neural networks through electrodes threaded directly into a person's brain has quietly made a difference in the lives of tens of thousands of people with Parkinson disease, essential tremor, and dystonia over the course of the past decade. But while it steadies patients' shaking limbs with surprising effect, its benefits on some patients' minds and personal lives have been more mixed.
The Department of Veterans Affairs will increase its corps of mental health professionals to try to cope with the increased demand from vets of the Iraq and Afghanistan wars.
Abbott today announced positive six-month results from the first 45 patients enrolled in the second stage of the ABSORB trial, which was presented during the Late-Breaking Clinical Trials session at the EuroPCR 2010 conference. At six months, Abbott's bioresorbable vascular scaffold (BVS) demonstrated strong results, with a low (4.4 percent) rate of major adverse cardiac events (MACE) and no blood clots (thromboses).
South African AIDS activist Thembi Ngubane recently died of drug-resistant tuberculosis at the age of 24, the AP/Washington Post reports (Nullis, AP/Washington Post, 6/14).
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Miss Casey Jo Bube, APNP N7082 Evergreen Dr, Rib Lake, WI 54470-9706 Ph: (715) 305-7017 | Miss Casey Jo Bube, APNP 2400 Pine Ridge Blvd, Wausau, WI 54401-7803 Ph: (715) 847-2022 |
News Archive
Amgen today announced detailed results from a new biomarker analysis of the pivotal Phase 3 "408" trial of Vectibix® (panitumumab) plus best supportive care compared to BSC alone. The analysis used massively parallel, next-generation sequencing technology to investigate whether mutations in nine genes known to be mutated in colorectal cancer, including the previously unanalyzed exon 3 mutation of the KRAS gene, are predictive of response to Vectibix in metastatic colorectal cancer.
A surgical treatment that stimulates distressed neural networks through electrodes threaded directly into a person's brain has quietly made a difference in the lives of tens of thousands of people with Parkinson disease, essential tremor, and dystonia over the course of the past decade. But while it steadies patients' shaking limbs with surprising effect, its benefits on some patients' minds and personal lives have been more mixed.
The Department of Veterans Affairs will increase its corps of mental health professionals to try to cope with the increased demand from vets of the Iraq and Afghanistan wars.
Abbott today announced positive six-month results from the first 45 patients enrolled in the second stage of the ABSORB trial, which was presented during the Late-Breaking Clinical Trials session at the EuroPCR 2010 conference. At six months, Abbott's bioresorbable vascular scaffold (BVS) demonstrated strong results, with a low (4.4 percent) rate of major adverse cardiac events (MACE) and no blood clots (thromboses).
South African AIDS activist Thembi Ngubane recently died of drug-resistant tuberculosis at the age of 24, the AP/Washington Post reports (Nullis, AP/Washington Post, 6/14).
› Verified 8 days ago